Loading stock…

Supernus Pharmaceuticals, Inc. (SUPN) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Supernus Pharmaceuticals, Inc.

SUPNMarket cap $2.45BPrice $42.1

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops and markets drugs for central nervous system disorders like epilepsy, ADHD, and migraine. Its blockbuster Trokendi XR and Qelbree generate the bulk of revenue, proving a small-cap biotech can thrive without a blockbuster mega-drug.

In Bastion Portfolios?

52W Return-16%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+3%4

Revenue Forecast

Rev CAGR (1y)+23%8

Rev CAGR (3y)+20%9

Rev CAGR (5y)+16%9

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+78%10

EPS Growth Y+3+51%9

Quality

Margins

EBIT Margin1%2

Net Income Margin-13%1

Free Cash Flow Margin2%3

Debt

Net Debt/EBITDA-2.610

Efficiency

ROE-10%1

ROA-8%1

Earnings Stability55

GEAR+AVERAGE53

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)137

P/E Ratio (Forward 3y)610

P/BV2.46

EV Multiples

EV/EBITDA Fwd144

EV/EBIT Fwd137

Yield

Free Cash Flow Yield0.8%3

Dividend Yieldna–

Momentum

Short term

1 month return+0%8

3 month return-14%3

YTD return-15%3

Mid term

Price vs 52wHigh71%4

1 year return-15%3

Long term

3 year return+54%6

5 year return+60%6

Risk Shield

Price Risk

Beta0.76

Volatility37%5

Free Cash Flow

Free Cash Flow Margin2%3

Free Cash Flow Yield0.8%3

Quality

ROCE1%2

Earnings Stability55

Net Debt/EBITDA-2.610

02Growth

Is it actually growing, and how fast?

SUPNSupernus Pharmaceuticals

Revenue FY25$719M

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+3%4

Revenue, next 1Y+23%8

Revenue, next 3Y, CAGR+20%9

Revenue, next 5Y, CAGR+16%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+78%10

EPS growth, FY28E+51%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue is set to grow 20%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 3%/yr over the last 3 years and is set to grow 20%/yr from here.

The runway holds up: revenue is set to grow 16%/yr over five years.9/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE36 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+0%8

3-month return-14%3

YTD return-15%3

MID & LONG-TERM▾SCORE

% of 52-week high71%4

1-year return-15%3

3-year return+54%6

5-year return+60%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+0%).

WATCH

Average long-term results. Multi-year returns are middling (+54% over three years and +60% over five), roughly average for the market.

WEAKNESSES

It's down 15% over the past year, now 29% below its 52-week high. That is a touch behind the market.

The stock is underperforming over three months (-14%) and so far this year (-15%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Supernus Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

SUPNSupernus Pharmaceuticals

Revenue FY25$719M

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+3%4

Revenue, next 1Y+23%8

Revenue, next 3Y, CAGR+20%9

Revenue, next 5Y, CAGR+16%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+78%10

EPS growth, FY28E+51%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue is set to grow 20%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 3%/yr over the last 3 years and is set to grow 20%/yr from here.

The runway holds up: revenue is set to grow 16%/yr over five years.9/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE36 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+0%8

3-month return-14%3

YTD return-15%3

MID & LONG-TERM▾SCORE

% of 52-week high71%4

1-year return-15%3

3-year return+54%6

5-year return+60%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+0%).

WATCH

Average long-term results. Multi-year returns are middling (+54% over three years and +60% over five), roughly average for the market.

WEAKNESSES

It's down 15% over the past year, now 29% below its 52-week high. That is a touch behind the market.

The stock is underperforming over three months (-14%) and so far this year (-15%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Supernus Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community